Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 1/2014

01-01-2014 | Breast Oncology

Predictors of Treatment with Mastectomy, Use of Sentinel Lymph Node Biopsy and Upstaging to Invasive Cancer in Patients Diagnosed with Breast Ductal Carcinoma In situ (DCIS) on Core Biopsy

Authors: Laura Chin-Lenn, MBBS, FRCSC, Lloyd A. Mack, MD, FRCSC, Walley Temple, MD, FRCSC, William Cherniak, MD, Robert R. Quinn, MD, PhD, Pietro Ravani, MD, PhD, Adriane M. Lewin, MSc, May Lynn Quan, MD, FRCSC

Published in: Annals of Surgical Oncology | Issue 1/2014

Login to get access

Abstract

Background

There are few established indications for sentinel lymph node biopsy (SLNB) in breast ductal carcinoma in situ (DCIS). This study examines factors contributing to the high rate of SLNB in DCIS in Alberta, Canada.

Methods

Patients who underwent definitive surgery from January 2009 to July 2011 for DCIS diagnosed on preoperative core-needle biopsy were identified using a provincial synoptic operative report database (WebSMR). The relationship between baseline patient and tumor characteristics and treatment with total mastectomy (TM), use of SLNB, and upstaging were examined.

Results

There were 394 patients identified in the study cohort. Mean age was 57 years, and average preoperative tumor size was 3 cm. Overall, 148 patients (37.6 %) underwent TM; predictors were preoperative tumor size [odds ratio (OR), 1.92 per 1-cm increase in size; 95 % CI 1.65–2.24] and surgeon. Upstaging to invasive cancer at surgery occurred in 23 %, predicted only by preoperative tumor size (OR 1.14 per 1 cm; 95 % CI 1.03–1.27). SLNB was performed in 306 patients overall (77 %) and 140 of those treated with BCS (61 %). Predictors of SLNB were larger preoperative tumor size (OR 1.55 per 1 cm; 95 % CI 1.18–2.04) and the surgeon. In patients treated with BCS, 3 patients who were upstaged had positive SLNs (>0.2 mm), and no patients with DCIS had a positive SLN.

Conclusions

SLNB use is high in patients undergoing BCS for DCIS. Tumor size and the operating surgeon predicted SLNB use. Despite a 23 % upstaging rate, the rate of clinically significant positive SLNs in patients treated with BCS is low, supporting omission of upfront SLNB.
Literature
1.
Jaffer S, Bleiweiss IJ. Histologic classification of ductal carcinoma in situ. Microsci Res Tech. 2002;59:92–101.CrossRef
2.
Brennan ME, Turner RM, Ciatto S, Marinovich ML, French JR, Macaskill P, et al. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology. 2011;260:119–28.PubMedCrossRef
3.
Olivotto I, Levine M, Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: the management of ductal carcinoma in situ (summary of the 2001 update). CMAJ. 2001;165:912–3.
4.
Lyman GH. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703–20.PubMedCrossRef
5.
6.
7.
8.
Quan ML. Treatment of DCIS: evaluation of a multidisciplinary disease specific approach. MSc thesis. Calgary: University of Calgary. 2005.
9.
Chin-Lenn L, Mack L, Temple WJ, Bryant HE, Craighead P, Quan ML. Using quality indicators to monitor changes in adherence to clinical practice guidelines for the treatment of ductal carcinoma in situ (DCIS) of the breast. Poster presented at: ASCO’s Quality Care Symposium. Nov 1–2, 2011; San Diego, CA.
10.
Canadian Institute for Health Information. Breast cancer surgery in Canada 2007–2008 to 2009–2010. Ottawa, Ontario: CIHI, 2012.
11.
Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004;96:443–8.PubMedCrossRef
12.
Rakovitch E, Pignol J-P, Chartier C, Hanna W, Kahn H, Wong J, et al. The management of ductal carcinoma in situ of the breast: a screened population-based analysis. Breast Cancer Res Treat. 2006;101:335–47.PubMedCrossRef
13.
Cutuli B, Lemanski C, Fourquet A, de Lafontan B, Giard S, Meunier A, et al. Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ: French Survey experience. Br J Cancer. 2009;100:1048–54.PubMedCentralPubMedCrossRef
14.
Tan JCC, McCready DR, Easson AM, Leong WL. Role of sentinel lymph node biopsy in ductal carcinoma-in situ treated by mastectomy. Ann Surg Oncol. 2006;14:638–45.PubMedCrossRef
15.
Shah DR, Canter RJ, Khatri VP, Bold RJ, Martinez SR. Utilization of lymph node assessment in patients with ductal carcinoma in situ treated with lumpectomy. J Surg Res. 2012;177:e21–6.PubMedCentralPubMedCrossRef
16.
Barthelmes L, Goyal A, Newcombe RG, McNeill F, Mansel RE, et al. Adverse reactions to patent blue V dye—The NEW START and ALMANAC experience. Eur J Surg Oncol. 2010;36:399–403.PubMedCrossRef
17.
Goldberg JI, Wiechmann LI, Riedel ER, Morrow M, Van Zee KJ. Morbidity of sentinel node biopsy in breast cancer: the relationship between the number of excised lymph nodes and lymphedema. Ann Surg Oncol. 2010;17:3278–86.PubMedCrossRef
18.
Fleissig A, Fallowfield LJ, Langridge CI, Johnson L, Newcombe RG, Dixon JM, et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat. 2006;95:279–93.PubMedCrossRef
19.
Estourgie SH, Valdés Olmos RA, Nieweg OE, Hoefnagel CA, Rutgers EJT, et al. Excision biopsy of breast lesions changes the pattern of lymphatic drainage. Br J Surg. 2007;94:1088–91.PubMedCrossRef
20.
Chagpar AB, Martin RC, Scoggins CR, Carlson DJ, Laidley AL, El-Eid SE, et al. Factors predicting failure to identify a sentinel lymph node in breast cancer. Surgery. 2005;138:56–63.PubMedCrossRef
21.
Javan H, Gholami H, Assadi M, Pakdel AF, Sadeghi R, Keshtgar M. The accuracy of sentinel node biopsy in breast cancer patients with the history of previous surgical biopsy of the primary lesion: Systematic review and meta-analysis of the literature. Eur J Surg Oncol. 2012;38:95–109.PubMedCrossRef
22.
Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927–33.PubMedCentralPubMedCrossRef
23.
Cox CE, Nguyen K, Gray RJ, Salud C, Ku NN, Dupont E, et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg. 2001;67:513–9.PubMed
24.
Pimiento JM, Lee MC, Esposito NN, Kiluk JV, Khakpour N, Carter WB, et al. Role of axillary staging in women diagnosed with ductal carcinoma in situ with microinvasion. J Oncol Pract. 2011;7:309–13.PubMedCentralPubMedCrossRef
25.
Kurniawan ED, Rose A, Mou A, Buchanan M, Collins JP, Wong MH, et al. Risk factors for invasive breast cancer when core needle biopsy shows ductal carcinoma in situ. Arch Surg. 2010;145:1098–104.PubMedCrossRef
26.
Sakr R, Bezu C, Raoust I, Antoine M, Ettore F, Darcourt J, et al. The sentinel lymph node procedure for patients with preoperative diagnosis of ductal carcinoma in situ: risk factors for unsuspected invasive disease and for metastatic sentinel lymph nodes. Int J Clin Pract. 2008;62:1730–5.PubMedCrossRef
27.
Goyal A, Douglas-Jones A, Monypenny I, Sweetland H, Stevens G, Mansel RE. Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 cases. Breast Cancer Res Treat. 2006;98:311–4.PubMedCrossRef
28.
Schneider C, Trocha S, McKinley B, Shaw J, Bielby S, Blackhurst D, et al. The use of sentinel lymph node biopsy in ductal carcinoma in situ. Am Surg. 2010;76:943–6.PubMed
29.
Dominguez FJ, Golshan M, Black DM, Hughes KS, Gadd MA, Christian R, et al. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ. Ann Surg Oncol. 2007;15:268–73.PubMedCrossRef
30.
Yen TWF, Hunt KK, Ross MI, Mirza NQ, Babiera GV, Meric-Bernstam F, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: A guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005;200:516–26.PubMedCrossRef
31.
Yen TWF, Shapiro SE, Gagel RF, Sherman SI, Lee JE, Evans DB. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery. 2003;134:890–9.PubMedCrossRef
32.
Prognostic importance of occult axillary lymph node micrometastases from breast cancers. International (Ludwig) Breast Cancer Study Group. Lancet. 1990;335:1565–8.
33.
Hainsworth PJ, Tjandra JJ, Stillwell RG, Machet D, Henderson MA, Rennie GC, et al. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg. 1993;80:459–63.PubMedCrossRef
34.
Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–75.PubMedCrossRef
35.
Takeshita T, Tsuda H, Moriya T, Yamasaki T, Asakawa H, Ueda S, et al. Clinical implications of occult metastases and isolated tumor cells in sentinel and non-sentinel lymph nodes in early breast cancer patients: serial step section analysis with long-term follow-up. Ann Surg Oncol. 2011;19:1160–6.PubMedCrossRef
36.
Intra M, Veronesi P, Mazzarol G, Galimberti V, Luini A, Sacchini V, et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg. 2003;138:309–13.PubMedCrossRef
37.
Wilkie C, White L, Dupont E, Cantor A, Cox CE. An update of sentinel lymph node mapping in patients with ductal carcinoma in situ. Am J Surg. 2005;190:563–6.PubMedCrossRef
38.
Pendas S, Dauway E, Giuliano R, Ku N, Cox CE, Reintgen DS. Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol. 2000;7:15–20.PubMedCrossRef
39.
Katz A, Gage I, Evans S, Shaffer M, Fleury T, Smith FP, et al. Sentinel lymph node positivity of patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg. 2006;191:761–6.PubMedCrossRef
40.
Lara JF, Young SM, Velilla RE, Santoro EJ, Templeton SF. The relevance of occult axillary micrometastasis in ductal carcinoma in situ. Cancer. 2003;98:2105–13.PubMedCrossRef
41.
El-Tamer M, Chun J, Gill M, Bassi D, Lee S, Hibshoosh H, et al. Incidence and clinical significance of lymph node metastasis detected by cytokeratin immunohistochemical staining in ductal carcinoma in situ. Ann Surg Oncol. 2005;12:254–9.PubMedCrossRef
42.
Diaz NM, Cox CE, Ebert M, Clark JD, Vrcel V, Stowell N, et al. Benign mechanical transport of breast epithelial cells to sentinel lymph nodes. Am J Surg Pathol. 2004;28:1641–5.PubMedCrossRef
43.
Tamhane R. The clinical significance of cytokeratin-positive cells in lymph nodes at the time of mastectomy from patients with ductal carcinoma-in situ. Ann Surg Oncol. 2002;9:999–1003.PubMedCrossRef
44.
Jeevan R, Cromwell DA, Trivella M, Lawrence G, Kearins O, Pereira J, et al. Reoperation rates after breast conserving surgery for breast cancer among women in England: retrospective study of hospital episode statistics. BMJ. 2012;345:e4505–5.PubMedCentralPubMedCrossRef
Metadata
Title
Predictors of Treatment with Mastectomy, Use of Sentinel Lymph Node Biopsy and Upstaging to Invasive Cancer in Patients Diagnosed with Breast Ductal Carcinoma In situ (DCIS) on Core Biopsy
Authors
Laura Chin-Lenn, MBBS, FRCSC
Lloyd A. Mack, MD, FRCSC
Walley Temple, MD, FRCSC
William Cherniak, MD
Robert R. Quinn, MD, PhD
Pietro Ravani, MD, PhD
Adriane M. Lewin, MSc
May Lynn Quan, MD, FRCSC
Publication date
01-01-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 1/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-3239-4

Other articles of this Issue 1/2014

Annals of Surgical Oncology 1/2014 Go to the issue

Melanomas

Surgical Management of Sentinel Lymph Node Biopsy Outside Major Nodal Basin in Patients with Cutaneous Melanoma

Breast Oncology

Value of Preoperative Ultrasound-Guided Axillary Lymph Node Biopsy for Preventing Completion Axillary Lymph Node Dissection in Breast Cancer: A Systematic Review and Meta-Analysis

Thoracic Oncology

Down-Regulation of Stromal Caveolin-1 Expression in Esophageal Squamous Cell Carcinoma: A Potent Predictor of Lymph Node Metastases, Early Tumor Recurrence, and Poor Prognosis

Healthcare Policy and Outcomes

Improving Multidisciplinary Cancer Conferences: A Population-Based Intervention

Breast Oncology

Intraoperative Imaging of Nipple Perfusion Patterns and Ischemic Complications in Nipple-Sparing Mastectomies

Translational Research and Biomarkers

The MicroRNA-21/PTEN Pathway Regulates the Sensitivity of HER2-Positive Gastric Cancer Cells to Trastuzumab